EVOKE PHARMA, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
EVOKE PHARMA, INC. had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $11.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-03-13
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.84M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.82M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.41M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2024-12-31 | $11.00K 10-K · filed 2025-03-13 | |
| 2023-12-31 | $1.84M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $1.82M 10-K/A · filed 2024-05-14 | |
| 2021-12-31 | $1.41M 10-K · filed 2023-03-21 | |
| 2020-12-31 | $1.14M 10-K · filed 2022-03-08 | $695.00K 10-K · filed 2021-03-11 |
| 2019-12-31 | $846.00K 10-K · filed 2021-03-11 | |
| 2018-12-31 | $574.00K 10-K · filed 2020-03-12 | |
| 2017-12-31 | $490.00K 10-K · filed 2019-03-06 | |
| 2016-12-31 | $539.00K 10-K · filed 2018-03-07 | |
| 2015-12-31 | $430.00K 10-K · filed 2017-03-15 | |
| 2014-12-31 | $223.00K 10-K · filed 2016-03-10 | |
| 2013-12-31 | $67.00K 10-K · filed 2015-03-04 |